Study urges caution with lenalidomide dosage; Drug found to interact with P-glycoprotein
Monday, August 8, 2011 - 17:30
in Health & Medicine
An early phase myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with another protein in cells that affect its dose level in the body. The drug is under study in more than 390 clinical trials for cancer and other diseases, and sometimes causes severe and life-threatening side effects. The findings could lead to safer dosing of lenalidomide in a variety of diseases.